An area pharmaceutical firm has signed a deal with the University of Missouri in hopes of developing a drug to treat cancer in dogs.
Lawrence-based CritiTech Inc. has reached an agreement with the Missouri College of Veterinary Medicine to study whether its drug Nanotax can be used in canines.
CritiTech, 1321 Wakarusa Drive, has long been developing Nanotax to treat cancer in human patients. But the company also believes the drug has potential for veterinary use. The deal with the University of Missouri will allow veterinarians to begin testing different dosage levels on dogs.
CritiTech leaders expect the study to take about 18 months to complete.